DelveInsight’s “Pulmonary Arterial Hypertension Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Pulmonary Arterial Hypertension market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan).
The Pulmonary Arterial Hypertension market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Pulmonary Arterial Hypertension: An Overview
Pulmonary Hypertension (PH) is defined as mean pulmonary artery pressure greater than 25 mm Hg at rest or greater than 30 mm Hg during exercise as measured by right heart catheterization. It is often characterized by a progressive and sustained increase in pulmonary vascular resistance (PVR) that eventually leads to right ventricular failure. It can be a life-threatening condition if untreated. The World Health Organization (WHO) has divided PH into five groups based on similarities in pathophysiology, clinical presentation, and therapeutic options.
The main purpose of treating Pulmonary Arterial Hypertension is to improve patients’ symptoms and slow the rate of clinical deterioration. General measures, supportive therapy, pharmacological treatment, and Surgical Treatment are used for treating pulmonary Arterial Hypertension (PAH). Patients
Treatment of patients with Pulmonary Arterial Hypertension is based on a patient’s vasoreactivity test and functional capacity as determined by the WHO functional capacity classification. The goal is to increase vasodilation of the pulmonary vasculature and decrease PAP to increase CO. The current mainstay therapies that include PDE5 inhibitors, sGC stimulators, ERAs, prostacyclin analog, and agonists for treating Pulmonary Arterial Hypertension target the three major pathways, NO/cGMP, endothelin, and prostacyclin.
Pulmonary Arterial Hypertension Market Key Facts
The Pulmonary Arterial Hypertension market size in the seven major markets was approximately USD 4,871.0 million in 2021, which is further expected to increase by 2032.
The market size in the 7MM will increase at a CAGR of 3.6% due to increasing awareness of the disease and the launch of emerging therapies.
Among the 7MM countries, the US accounted for the highest market size of Pulmonary Arterial Hypertension, with approximately USD 3,848.1 million in 2021.
The total Pulmonary Arterial Hypertension prevalent cases in the 7MM were estimated to be approximately 87,000+ cases in 2021, which are expected to increase by 2032.
According to DelveInsight estimates, in 2021, the total diagnosed prevalent cases of Pulmonary Arterial Hypertension were estimated to be approximately 52,600+ in the 7MM.
Among the 7MM, the United States accounted for nearly 58% of the total diagnosed prevalent cases of Pulmonary Arterial Hypertension in the 7MM in the year 2021.
Some of the key players in the Pulmonary Arterial Hypertension Market include Pfizer, Eli Lilly and Company, United Therapeutics Corporation, Gilead Sciences, GSK, ICOS Corporation, Actelion Pharmaceuticals, Nippon Shinyaku, Bayer Group, Actelion Pharmaceuticals, Co Therix, Kaken Pharmaceutical, Sanofi-Aventis, Toray, Acceleron Pharma Inc., Altavant Sciences, Aerovate Therapeutics, Respira Therapeutics, Gossamer Bio Inc., Merck Sharp & Dohme Corp., Insmed Incorporated, Pharmaosa Biopharma Inc., Bial (Portela C S.A.), Liquida Technologies, Inc., Cereno Scientific AB, and others.
According to DelveInsight, the overall dynamics of the Pulmonary Arterial Hypertension market are anticipated to change in the coming years owing to the expected launch of emerging therapies.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Pulmonary Arterial Hypertension market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Pulmonary Arterial Hypertension market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Pulmonary Arterial Hypertension Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
The Report Covers the Pulmonary Arterial Hypertension Epidemiology, Segmented by –
Total Prevalent Patient Population of Pulmonary Arterial Hypertension in the 7MM (2019–2032)
Sub-type Specific Prevalence of Pulmonary Arterial Hypertension in the 7MM (2019–2032)
Gender-specific Prevalence of Pulmonary Arterial Hypertension in the 7MM (2019–2032)
Pulmonary Arterial Hypertension Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pulmonary Arterial Hypertension market or expected to get launched during the study period. The analysis covers the Pulmonary Arterial Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Pulmonary Arterial Hypertension Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Pulmonary Arterial Hypertension Market Will Evolve by 2032 @
Pulmonary Arterial Hypertension Therapeutics Analysis
The increase in this disease’s prevalence and approval of pipeline therapies shall positively impact the market in the coming years. While the current FDA-approved drugs improve the quality of life and hemodynamic parameters, none offer a cure for Pulmonary Arterial Hypertension. Extensive research efforts have led to the emergence of innovative therapeutic approaches in the area of Pulmonary Arterial Hypertension.
Some of the Leading Companies in the Pulmonary Arterial Hypertension Therapeutics Market Include
And Many Others
Pulmonary Arterial Hypertension Drugs Covered in the Report Include:
Sotatercept (MK-7962) (Merck)
Ralinepag (United Therapeutics)
RT234 (vardenafil inhalation powder) (Respira Therapeutics)
Seralutinib (GB002) (Gossamer Bio)
YUTREPIA (inhaled dry powder formulation of treprostinil) (Liquidia Technologies)
TNX-201 (Tenax Therapeutics)
RVT-1201 (Altavant Sciences)
Bardoxolone methyl (Reata Pharmaceuticals, Inc.)
PB1046 Injection (PhaseBio Pharmaceuticals Inc.)
CXA-10 (Complexa, Inc.)
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More:
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Pulmonary Arterial Hypertension Competitive Intelligence Analysis
4. Pulmonary Arterial Hypertension Market Overview at a Glance
5. Pulmonary Arterial Hypertension Disease Background and Overview
6. Pulmonary Arterial Hypertension Patient Journey
7. Pulmonary Arterial Hypertension Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Pulmonary Arterial Hypertension Treatment Algorithm, Current Treatment, and Medical Practices
9. Pulmonary Arterial Hypertension Unmet Needs
10. Key Endpoints of Pulmonary Arterial Hypertension Treatment
11. Pulmonary Arterial Hypertension Marketed Products
12. Pulmonary Arterial Hypertension Emerging Drugs and Latest Therapeutic Advances
13. Pulmonary Arterial Hypertension Seven Major Market Analysis
14. Attribute Analysis
15. Pulmonary Arterial Hypertension Market Outlook (In US, EU5, and Japan)
16. Pulmonary Arterial Hypertension Access and Reimbursement Overview
17. KOL Views on the Pulmonary Arterial Hypertension Market
18. Pulmonary Arterial Hypertension Market Drivers
19. Pulmonary Arterial Hypertension Market Barriers
21. DelveInsight Capabilities
Download Sample PDF to Explore the Key Offerings of the Report:
Other Trending Healthcare Reports By DelveInsight
“Pulmonary Arterial Hypertension – Pipeline Insight, 2023” report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in the Pulmonary Arterial Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States